Tuesday, 17 November 2026Peptide medicines at the counter: price, coverage, supply, rules.

Reading as
What is this?
PriceUS

CVS Health puts the GLP 1 break even price at $350 a month for health plans

Aetna claims analysed by CVS Health show GLP 1 users went to hospital less, but plans still paid about $3,900 more per member in year three. CVS models a net price near $350 a month as the point where savings and drug costs meet.

Editorial illustration for the story: CVS Health puts the GLP 1 break even price at $350 a month for health plans
Illustration: Peptide Town. Cut-paper collage, not data.

Who feels it

  • Payers Rethink

    A $350 net price is CVS benchmark for break even; current net costs above it mean higher plan spend.

  • Patients Adjust

    Plans may narrow weight loss cover to higher risk patients, pushing others toward cash prices or stopping.

  • Prescribers Worth knowing

    Expect tighter criteria that favour diabetes and heart risk over weight loss alone.

  • Pharmacies Worth knowing

    More claims may be rejected for weight loss and moved to cash or maker programs at the counter.

  • Sellers Worth knowing

    Makers face pressure from a large benefit manager to bring net prices down toward cash levels.

CVS Health has put a figure on the GLP 1 break even price for health plans: a net cost of about $350 a month, held for three years. Below that level, the company says, lower hospital and emergency spending would roughly cancel out what plans pay at the pharmacy. The estimate comes from a CVS white paper built on Aetna claims and was reported on November 14 and 15. It arrives as employers lock in their 2027 plans, and it puts a dollar value on why many have been pulling weight loss cover.

What the Aetna claims showed

The analysis used anonymized Aetna claims from commercially insured members who started a GLP 1 drug between 2023 and 2025, followed for up to three years. Fox affiliates, citing Reuters, put the group at about 60,000 people treated for obesity, diabetes and other conditions. Each starter was matched with a similar person who did not take the drugs, using age, existing illness, earlier use of care and past medical and pharmacy spending. According to Insurance Business, which reviewed the paper, hospitalization rates among starters ran 34 to 42 percent below their matches over the follow up. Emergency visits were 10 to 12 percent lower in the first and second years. People who kept taking the drug on at least 80 percent of days did better still on both measures.

The money moved the other way. In the third year, medical spending was about $9,400 lower per member among all starters, but pharmacy spending was $13,300 higher, a net rise of roughly $3,900 per person. For members who stayed on treatment, medical savings grew to $13,000, yet the extra drug bill grew faster, to $20,300, leaving a net increase of $7,300. CVS warned that fewer people reached year three than earlier checkpoints, so some differences could be chance. Fox reported that about 4,000 people were still on the drugs after three years. In plain terms, the drugs kept people out of hospital, and the plan still paid more overall at the prices in force during the study years.

Where the $350 net price comes from

CVS says its internal model found that a net price near $350 a month across three years would bring drug spending and the observed medical savings into balance for the whole study group. The figure moves with the patient: risk, how long people stay on treatment and the reason for prescribing all shift it. Amy Compton-Phillips, the chief medical officer of CVS Health, told Reuters that an older person with diabetes faces a higher risk of hospital care than a younger person with obesity alone. "The higher-risk the person is, the quicker you get to a return on investment," she said. That logic favours paying for patients with diabetes or heart disease first and treating lower risk weight loss cases as a harder case for any plan to justify on cost alone.

CVS says its internal model found that a net price near $350 a month across three years would bring drug spending and the observed medical savings into balance for the whole study group.

Net price means what a plan pays after rebates and discounts, not the sticker figure. Fox reported list prices above $1,000 a month, and insurers rarely publish what they actually pay. The Washington Post has reported that pharmacy benefit managers such as CVS Caremark negotiate rebates that bring the plan cost below the $449 self pay level, according to Fox. That leaves an open question for readers: nobody outside the contracts knows how far today's net cost sits above the GLP 1 break even price. The gap could be small for some plans and large for others. The table below sets out the figures that Insurance Business and Fox attributed to the white paper, for all starters and for those who stayed on treatment.

MeasureAll startersStayed on treatment
Hospitalization rate versus matched non users34 to 42% lower53 to 66% lower
Emergency visit rate10 to 12% lower in years one and two27 to 33% lower
Medical spending in year threeabout $9,400 lowerabout $13,000 lower
Pharmacy spending in year threeabout $13,300 higherabout $20,300 higher
Net change in year threeabout $3,900 higherabout $7,300 higher

Direct to consumer prices already sit near the line

Cash prices from the two makers already cluster around the GLP 1 break even price that CVS describes. Fox reported that people without insurance can get the drugs directly from Eli Lilly and Novo Nordisk for $149 to $449 a month, depending on the dose, and both firms take part in the federal TrumpRx site. Insurance Business noted that Lilly's Employer Connect program, launched in March 2026, offers the Zepbound KwikPen to employers at a flat net $449 a month. Compton-Phillips told Reuters that these direct to consumer prices suggest the makers can still earn money while charging under $350. Fox said it asked Lilly and Novo for comment, and that reading of their margins is the view of CVS, not of the companies.

A low cash price does not settle the bill for people with insurance, CVS argues. A patient paying cash carries the whole cost alone, while a plan spreads it across every member through premiums. The Kaiser Family Foundation's 2026 employer survey put the average family premium at $28,303 a year, 5 percent higher than in 2025, and GLP 1 drugs are a growing slice of that spend. Insurance Business also quoted Jennifer Collier of Sun Life US on why people stop treatment. "Most Americans don't have $800, $1,000 in disposable cash," she said. For a worker whose plan drops cover, the choice is between a cash price, a cheaper drug or stopping, and each route carries its own risk of lost progress.

What it means for employer coverage in 2027

CVS frames the decision for plans around three tests: treat the patients most likely to benefit, help them stay on treatment, and pay a price that makes wider use affordable. "The analysis does not suggest that financial break-even should be the sole measure of a medicine's value," the company said, while adding that price explains why plans struggle to widen access. Its own numbers point the same way as the five year study we covered last month, which found other medical costs did not fall enough to offset the drugs. For employers, the likely result is narrower rules for weight loss rather than a full exit, with diabetes and heart patients kept at the front of the line.

The adherence finding is the awkward one for employer coverage. People who stayed on treatment had the best health results and also the highest total cost, because they used more of the drug. That means adherence programs sold to employers can improve outcomes while widening the cost gap, unless the net price falls at the same time. The trend among large employers has been to cover fewer workers for weight loss as 2027 costs climb. We could not find the full white paper, titled GLP-1s: Good Drugs, High Prices, on the CVS website, so most figures here come from Insurance Business reporting on the paper. The rest rely on the Fox account of Reuters interviews.

Conclusion

The GLP 1 break even price that CVS Health puts at about $350 a month is a model result, not a market price, and it shifts with patient risk and adherence. It still gives employers and insurers a clear marker for 2027 talks with drug makers and benefit managers. For patients, the near term effect is more pressure on who qualifies for cover, and more use of cash routes when plans say no. This is research and policy reporting, not medical or financial advice.

Source CVS Health white paper on Aetna claims (GLP-1s: Good Drugs, High Prices), as reported by Insurance Business and by FOX 4 citing Reuters, November 14 and 15, 2026

Spotted an error? Tell us through the contact form; we follow the corrections policy.